Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Irati Macaya, Marta Román, Connor Welch, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10

Showing 10 citing articles:

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Targeting MEK in non-small cell lung cancer
Matthew S Lara, Collin M. Blakely, Jonathan W. Riess
Current Problems in Cancer (2024) Vol. 49, pp. 101065-101065
Open Access | Times Cited: 5
Towards a more inductive world for drug repurposing approaches
Jesús de la Fuente, Guillermo Serrano, Uxía Veleiro, et al.
Nature Machine Intelligence (2025)
Open Access
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
Diego J. Jiménez, Aadil Javed, Teresa Rubio‐Tomás, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2860-2860
Open Access | Times Cited: 3
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
A. Puyalto, María Rodríguez‐Remírez, Inés López, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
Diego J Jiménez, Aadil Javed, Teresa Rubio‐Tomás, et al.
(2024)
Open Access | Times Cited: 2
Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC
Varsha Tripathi, Aishwarya Khare, Divyanshi Shukla, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112682-112682
Closed Access | Times Cited: 1
Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in KRAS‐driven lung adenocarcinoma
Jiang Ji, Pengfei Ye, Ning-Ning Sun, et al.
Cancer Communications (2024) Vol. 44, Iss. 11, pp. 1350-1373
Open Access | Times Cited: 1
KRAS inhibitors in drug resistance and potential for combination therapy
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma
Ruipei Xiao, Wenli Zhao, Wei Lin, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009212-e009212
Open Access
Page 1

Scroll to top